DE102004028973A1 - Substituierte Tetrahydro-2H-isochinolin-1-on-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament - Google Patents

Substituierte Tetrahydro-2H-isochinolin-1-on-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament Download PDF

Info

Publication number
DE102004028973A1
DE102004028973A1 DE102004028973A DE102004028973A DE102004028973A1 DE 102004028973 A1 DE102004028973 A1 DE 102004028973A1 DE 102004028973 A DE102004028973 A DE 102004028973A DE 102004028973 A DE102004028973 A DE 102004028973A DE 102004028973 A1 DE102004028973 A1 DE 102004028973A1
Authority
DE
Germany
Prior art keywords
alkyl
heteroaryl
phenyl
hydroxy
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE102004028973A
Other languages
German (de)
English (en)
Inventor
Stefan Dr. Arlington Peukert
Stefan Dr. Guessregen
Armin Dr. Hofmeister
Herman Dr. Schreuder
Uwe Dr. Schwahn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Sanofi Aventis Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland GmbH filed Critical Sanofi Aventis Deutschland GmbH
Priority to DE102004028973A priority Critical patent/DE102004028973A1/de
Priority to CN2005800201245A priority patent/CN1968929B/zh
Priority to HK07108325.2A priority patent/HK1100409B/xx
Priority to KR1020067026566A priority patent/KR101169919B1/ko
Priority to CA2570942A priority patent/CA2570942C/en
Priority to AU2005254632A priority patent/AU2005254632B2/en
Priority to BRPI0512139-6A priority patent/BRPI0512139A/pt
Priority to JP2007515811A priority patent/JP4928446B2/ja
Priority to PCT/EP2005/005871 priority patent/WO2005123687A1/de
Priority to EP05754335.7A priority patent/EP1758864B1/de
Priority to MXPA06013876A priority patent/MXPA06013876A/es
Publication of DE102004028973A1 publication Critical patent/DE102004028973A1/de
Priority to IL179758A priority patent/IL179758A/en
Priority to US11/567,352 priority patent/US7795278B2/en
Priority to US12/850,328 priority patent/US20110021462A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
DE102004028973A 2004-06-16 2004-06-16 Substituierte Tetrahydro-2H-isochinolin-1-on-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament Withdrawn DE102004028973A1 (de)

Priority Applications (14)

Application Number Priority Date Filing Date Title
DE102004028973A DE102004028973A1 (de) 2004-06-16 2004-06-16 Substituierte Tetrahydro-2H-isochinolin-1-on-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
JP2007515811A JP4928446B2 (ja) 2004-06-16 2005-06-01 置換されたテトラヒドロ−２ｈ−イソキノリン−１−オン誘導体、その製造方法及び薬剤としてのその使用
PCT/EP2005/005871 WO2005123687A1 (de) 2004-06-16 2005-06-01 Substituierte tetrahydro-2h-isochinolin-1-on-derivate, verfahren zu ihrer herstellung und ihre verwendung als medikament
KR1020067026566A KR101169919B1 (ko) 2004-06-16 2005-06-01 치환된 테트라하이드로-2ｈ-이소퀴놀린-1-온 유도체, 이의제조방법 및 약제로서의 이의 용도
CA2570942A CA2570942C (en) 2004-06-16 2005-06-01 Substituted tetrahydro-2h-isoquinolin-1-one derivatives, method for the production thereof, and use of the same as medicament
AU2005254632A AU2005254632B2 (en) 2004-06-16 2005-06-01 Substituted tetrahydro-2H-isoquinolin-1-one derivatives, method for the production thereof, and use of the same as medicaments
BRPI0512139-6A BRPI0512139A (pt) 2004-06-16 2005-06-01 derivados tetraidro-2h-isoquinolin-1-ona substituìdos, método para sua produção e uso do mesmo como medicamento
CN2005800201245A CN1968929B (zh) 2004-06-16 2005-06-01 取代的四氢-2h-异喹啉-1-酮衍生物、其制备方法以及其作为药物的用途
HK07108325.2A HK1100409B (en) 2004-06-16 2005-06-01 Substituted tetrahydro-2h-isoquinolin-1-one derivatives, method for the production thereof, and use of the same as medicaments
EP05754335.7A EP1758864B1 (de) 2004-06-16 2005-06-01 Substituierte Tetrahydro-2H-isochinolin-1-on-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente
MXPA06013876A MXPA06013876A (es) 2004-06-16 2005-06-01 Derivados de tetrahidro-2h-isoquinolin-1-ona sustituida, metodo para su produccion, y uso de los mismos como medicamentos.
IL179758A IL179758A (en) 2004-06-16 2006-11-30 Substituted tetrahydro-2h-isoquinolin-1-one derivatives, method for the production thereof and use of the same as medicaments
US11/567,352 US7795278B2 (en) 2004-06-16 2006-12-06 Substituted tetrahydro-2H-isoquinolin-1-one derivatives, and methods for the production and use thereof
US12/850,328 US20110021462A1 (en) 2004-06-16 2010-08-04 Substituted tetrahydro-2h-isoquinolin-1-one derivatives, and methods for the production and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004028973A DE102004028973A1 (de) 2004-06-16 2004-06-16 Substituierte Tetrahydro-2H-isochinolin-1-on-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament

Publications (1)

Publication Number Publication Date
DE102004028973A1 true DE102004028973A1 (de) 2006-01-05

Family

ID=35057156

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102004028973A Withdrawn DE102004028973A1 (de) 2004-06-16 2004-06-16 Substituierte Tetrahydro-2H-isochinolin-1-on-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament

Country Status (12)

Country Link
US (2) US7795278B2 (https=)
EP (1) EP1758864B1 (https=)
JP (1) JP4928446B2 (https=)
KR (1) KR101169919B1 (https=)
CN (1) CN1968929B (https=)
AU (1) AU2005254632B2 (https=)
BR (1) BRPI0512139A (https=)
CA (1) CA2570942C (https=)
DE (1) DE102004028973A1 (https=)
IL (1) IL179758A (https=)
MX (1) MXPA06013876A (https=)
WO (1) WO2005123687A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200808709A (en) 2006-03-31 2008-02-16 Glaxo Group Ltd Novel compounds
CA2726588C (en) 2008-06-03 2019-04-16 Karl Kossen Compounds and methods for treating inflammatory and fibrotic disorders
US8735391B2 (en) 2008-09-26 2014-05-27 University Of Kansas Synthesis of functionalized octahydro-isoquinolin-1-one-8-carboxamides, octahydro-isoquinolin-1-one-8-carboxylic esters and analogs, and therapeutic methods
ES2443127T3 (es) * 2008-11-11 2014-02-17 Jeil Pharmaceutical Co., Ltd. Nuevos derivados tricíclicos o sales de éstos farmacéuticamente aceptables, su procedimiento de fabricación y composiciones farmacéuticas que los contienen
WO2010081778A1 (en) 2009-01-17 2010-07-22 Universität Zürich Blockers of parp for the prevention and treatment of helicobacter pylori induced gastric cancer
TWI499418B (zh) * 2009-05-21 2015-09-11 Nerviano Medical Sciences Srl 異喹啉－１（２ｈ）－酮衍生物
CN101602725B (zh) * 2009-07-21 2012-07-11 浙江大学 六氢异喹啉酮类化合物的合成方法
WO2011058367A2 (en) 2009-11-13 2011-05-19 Astrazeneca Ab Diagnostic test for predicting responsiveness to treatment with poly(adp-ribose) polymerase (parp) inhibitor
JP2013531687A (ja) 2010-07-16 2013-08-08 パーデュー、ファーマ、リミテッド、パートナーシップ ナトリウムチャネル遮断剤としてのピリジン化合物
WO2013136170A1 (en) 2012-03-16 2013-09-19 Purdue Pharma L.P. Substituted pyridines as sodium channel blockers
AR092742A1 (es) * 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
WO2014096941A1 (en) 2012-12-20 2014-06-26 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
US10730866B2 (en) 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof
CN105272936B (zh) * 2014-05-27 2019-05-17 中国科学院上海药物研究所 一类氮芳基苯并噻唑类parp抑制剂及其制备方法和用途
CN104163796A (zh) * 2014-08-04 2014-11-26 上海师范大学 一类取代的1,2,3,4-四氢喹啉-4-酮盐酸盐的制备方法
PH12017502228B1 (en) * 2015-06-09 2022-08-03 Onconic Therapeutics Inc Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same
JP6457696B2 (ja) 2015-07-23 2019-01-23 アンスティテュ・キュリＩｎｓｔｉｔｕｔ Ｃｕｒｉｅ 癌を処置するためのＤｂａｉｔ分子とＰＡＲＰインヒビターとの組合せの使用
GB201519573D0 (en) 2015-11-05 2015-12-23 King S College London Combination
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
WO2018197461A1 (en) 2017-04-28 2018-11-01 Akribes Biomedical Gmbh A parp inhibitor in combination with a glucocorticoid and/or ascorbic acid and/or a protein growth factor for the treatment of impaired wound healing
KR20200130856A (ko) 2018-03-13 2020-11-20 옹쎄오 암 치료에서 획득한 내성에 대한 디베이트 분자
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CN114437072B (zh) * 2020-10-30 2023-03-31 中国科学院大连化学物理研究所 一种6-甲基异吲哚并[2,1-a]喹喔啉类化合物的合成方法
GB202217888D0 (en) * 2022-11-29 2023-01-11 Duke Street Bio Ltd Pharmaceutical compound
KR20260030809A (ko) 2023-06-21 2026-03-06 테트라곤 바이오사이언시스 엘티디 Hr 능숙형 암을 치료하는 방법에 사용하기 위한 데옥시시티딘 유도체 및 parp 억제제를 포함하는 조합

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3594380A (en) * 1969-02-18 1971-07-20 American Home Prod Isoquinolin-1(2h)-ones
CA1334969C (en) * 1988-08-19 1995-03-28 Mark James Suto Substituted dihydroisoquinoline and phthalazine derivatives as potentiators of the lethal effects of radiation and certain chemotherapeutic agents, selected compounds, analogs andprocess
US20020022636A1 (en) * 1997-09-03 2002-02-21 Jia-He Li Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity
US6444676B1 (en) * 1999-12-20 2002-09-03 Iok-Hou Pang Use of PARP inhibitors in the treatment of glaucoma
DE60218458T2 (de) * 2001-05-08 2007-11-15 Kudos Pharmaceuticals Ltd. Isochinolinon derivate als parp inhibitoren
JP2004043458A (ja) * 2002-05-22 2004-02-12 Kyorin Pharmaceut Co Ltd ４−アリール−５−ヒドロキシイソキノリン誘導体およびその製造法
DE10233388A1 (de) * 2002-07-23 2004-02-12 Basf Ag Verfahren zur kontinuierlich betriebenen Reindestillation des bei der koppel-produktfreien Propylenoxidsynthese verwendeten Lösungsmittels Methanol unter gleichzeitiger Abtrennung der Methoxypropanole und der Schwersieder
AU2003264386A1 (en) * 2002-09-10 2004-04-30 Kyorin Pharmaceutical Co., Ltd. 4-(substituted aryl)-5-hydroxyisoquinolinone derivative
PE20060285A1 (es) * 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)

Also Published As

Publication number Publication date
CA2570942A1 (en) 2005-12-29
IL179758A0 (en) 2007-05-15
CN1968929A (zh) 2007-05-23
IL179758A (en) 2010-12-30
EP1758864B1 (de) 2013-04-10
CA2570942C (en) 2012-12-11
US20110021462A1 (en) 2011-01-27
HK1100409A1 (zh) 2007-09-21
KR101169919B1 (ko) 2012-08-06
JP4928446B2 (ja) 2012-05-09
US20070142430A1 (en) 2007-06-21
MXPA06013876A (es) 2007-03-07
US7795278B2 (en) 2010-09-14
CN1968929B (zh) 2010-09-08
AU2005254632A1 (en) 2005-12-29
EP1758864A1 (de) 2007-03-07
BRPI0512139A (pt) 2008-02-12
AU2005254632B2 (en) 2011-09-15
KR20070024612A (ko) 2007-03-02
WO2005123687A1 (de) 2005-12-29
JP2008502614A (ja) 2008-01-31

Similar Documents

Publication Publication Date Title
EP1758864B1 (de) Substituierte Tetrahydro-2H-isochinolin-1-on-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikamente
DE60315516T2 (de) Pyridazinon-derivate als cdk2-hemmer
EP1802578B1 (de) 3,6-substituierte 5-arylamino-1h-pyidin-2-on derivative und verwandte verbindungen als poly(adp-ribose)polymerase (parp) inhibitoren zur behandlung von durch nekose oder apoptose verursachten gewebeschäden oder erkankungen
EP1399423B1 (de) Anthranilsäureamide mit heteroarylsulfonyl-seitenkette und ihre verwendung als antiarrhythmische wirkstoffe
DE69725465T2 (de) 6-phenylpyridyl-2-amin-derivate verwendbar als nos-inhibitoren
DE60315615T2 (de) Tricyclische verbindungen basierend auf thiophen und arzneimittel, die diese umfassen
DE69622532T2 (de) Glycoprotein iib/iiia-antagonisten
DE102004010194A1 (de) 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate, ihre Herstellung und Verwendung in Arzneimitteln
DD291559A5 (de) Verfahren zur herstellung von 3-(1,2,5,6-tetrahydropyridyl)-pyrrolopyridinen
KR20160006207A (ko) 사이클로알킬산 유도체, 그의 제조 방법, 및 그의 약학적 용도
DE2065636A1 (de) Neue tricyclische verbindungen
DE2341965A1 (de) N- eckige klammer auf 1-(omegaphenylalkyl)-piperidyl-4 eckige klammer zu -n-(alpha-pyridyl)-carbonsaeureamide, deren saeureadditionssalze, verfahren zu deren herstellung, sowie deren verwendung als arzneimittel
DE102004010207A1 (de) Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate
DE3049959C2 (https=)
DE102005028862A1 (de) Substituierte Heterocyclen, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DD293349A5 (de) Verfahren zur herstellung neuer thiouracilderivate und ihrer saeureadditionssalze
DE69008565T2 (de) Aminoalkoxyphenyl-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende Zusammensetzungen.
EP0731801B1 (de) Substituierte aminoalkylaminopyridine
DE2221808C2 (de) Hydrazinopyridazin-Derivate, deren Säureadditionssalze, Verfahren zu deren Herstellung und Heilmittel
EP0957092A1 (de) Anellierte Dihydropyridine und deren Verwendung für die Herstellung von pharmazeutischen Zubereitungen
HK1100409B (en) Substituted tetrahydro-2h-isoquinolin-1-one derivatives, method for the production thereof, and use of the same as medicaments
CH619461A5 (en) Process for the preparation of heterocyclic compounds
DE3116791A1 (de) "4,5-dihydro-6-(pyridinyl)-3(2h)-pyridazinone, wertvoll als kardiotonische mittel, und ihre herstellung"

Legal Events

Date Code Title Description
OM8 Search report available as to paragraph 43 lit. 1 sentence 1 patent law
R005 Application deemed withdrawn due to failure to request examination

Effective date: 20110616